Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,456 total articles
DNOW appears mispriced relative to balance-sheet strength and recurring free cash flow. The shares trade near 1.17x book and 0.73x sales, while the company generates positive free cash flow and carries modest leverage. Short-term headline risk and a negative EPS readout have pushed the stock below earlier levels; we see a mid-term opportunity to bu…
General Dynamics (GD) combines steady organic growth, strong free cash flow and a manageable balance sheet with direct exposure to rising naval and defense budgets. Trading at ~22x trailing earnings with an EV/EBITDA of 16.4 and free cash flow of roughly $6.2B, GD looks like a defensive-growth name you can own through geopolitical noise. This is a …
Red Cat (RCAT) is a high-volatility, high-upside drone play. Recent product launches (Hellcat on 06/15/2026), ramping maritime production and Pentagon programs are beginning to show up in orders and partner integrations. At the same time the stock trades with a $1.82B market cap, negative earnings and stretched multiples. This trade targets near-te…
Thales is well positioned to benefit from a multi-year increase in defense and secure communications spending. Buy into weakness with a clear entry at $80.00, a protective stop at $68.00 and a $100.00 target over a long-term (180 trading days) horizon. The setup balances asymmetric upside from large program awards and margin expansion against execu…
Cisco owns the enterprise networking stack that underpins large-scale AI deployments. Strong cash flow, low leverage, and a valuation that still lags direct AI infrastructure players make CSCO an actionable mid-term long. Entry $120.20, target $140.00, stop $112.00; horizon 45 trading days.
Ryanair's ultra-low-cost model, healthy balance-sheet footprint and recent market momentum make it the likeliest European carrier to recover first from the jet-fuel shock tied to the Middle East. This trade lays out a clear entry at $62.00, a stop at $55.00 and a target at $74.24 (the 52-week high), with a 180-trading-day horizon.
Plains All American (PAA) yields roughly 7% today, trades at modest multiples (P/FCF ~7.5, EV/EBITDA ~11.7) and generates meaningful free cash flow. With a pending NGL sale that simplifies the business and support for distributions, I recommend a long trade for income and capital appreciation over a 180 trading day horizon, entry $22.00, target $26…
Atlassian is staging a disciplined recovery after the post-SaaSpocalypse sell-off. Positive free cash flow, reasonable EV/sales and shrinking short interest combined with AI-driven demand for collaboration tools make a compelling mid-term trade. Entry at $92.00, stop at $81.00, target at $125.00 — mid term (45 trading days) plan that balances upsid…
Fluence (FLNC) is trading at a valuation that reflects execution risk, capital intensity and a volatile revenue ramp. Recent commercial wins with hyperscalers and a structurally expanding BESS market make a controlled long trade attractive. Enter at $24.00, stop $19.50, target $33.50 over a mid-term 45 trading day horizon; position size should refl…
AST SpaceMobile (ASTS) trades like a high-beta growth name but has quietly become a credible defense supplier and launch partner client, creating a practical pathway from speculative broadband dreams toward contract-backed revenue. This trade idea lays out a long entry at $87.60, a stop at $72.00 and a target of $125.00 over a long-term (180 tradin…
Lumen is transitioning from a legacy consumer-heavy footprint to an enterprise-focused provider of fiber and AI-optimized networking. Recent NaaS wins, a materially lower share price from last year's peak, and an improving cash profile create a trade that offers upside to $10.50 while limiting downside risk with a $7.25 stop. We lay out the thesis,…
Wintrust shares have run up near their 52-week highs while airborne short interest and elevated valuation leave the stock vulnerable to a catalyst that shifts sentiment toward downgrades. This trade idea lays out a tactical short with a clear entry, stop, and target over a mid-term (45 trading days) horizon.
AMD is trading near $547 after a dramatic rerating as agentic AI shifts demand toward inference-optimized CPUs and accelerators. Fundamentals show robust free cash flow ($8.57B) and a clean balance sheet (debt/equity ~0.05), but valuation is stretched (P/E ~168, price/sales ~22.3). This trade idea lays out a mid-term long: entry $547.27, stop $485.…
Trilogy Metals (TMQ) is a speculative copper play trading near $4.07 with a market cap around $716M. Recent U.S. government involvement and the company's Bornite/Arctic projects create a near-term narrative; this trade idea targets $6.50 on a 45-trading-day horizon with a $3.10 stop, but carries significant execution, permitting and financing risk.
LendingClub's evolution from a marketplace lender to a digital, deposit-taking bank is moving from strategy into results. With origination growth re-accelerating, net charge-offs declining and valuation sitting near 1.3x book and ~12x earnings, the stock offers asymmetric upside if execution continues. This trade idea lays out an entry, stop and ta…
Salesforce ($CRM) is positioning itself as the connective tissue between enterprise data and AI agents. The stock has pulled back to $165 after a 52-week peak near $277; the balance sheet and free cash flow support continued investment in Data 360, Agentforce, and recently acquired integration tooling. This trade idea targets $210 with a hard stop …
Sanofi looks attractively valued against a $106.6B market cap, a ~3.99% yield and improving specialty franchise momentum. Recent regulatory progress and signs of commercial durability in its specialty portfolio make a long trade with a clear entry, stop and target compelling over a 180 trading-day horizon.
Avantis U.S. Equity ETF (AVUS) is trading near a fresh 52‑week high while its moving averages and inflows point to steady accumulation. We lay out a mid‑term (45 trading days) trade plan with entry, stop and target, and explain why a modest long makes sense versus a flat benchmark exposure.
South Korea's market has been the year-to-date leader thanks to memory demand; EWY is a concentrated, liquid way to play that theme. I prefer a tactical long in EWY over broader alternatives: entry $211.47, stop $195.00, target $235.00, mid term (45 trading days). The trade balances upside from continued AI-driven memory demand and ETF flows agains…
NIQ Global Intelligence is showing an earnings recovery and free cash flow strength that the market has not fully priced. With management buying stock, $214.5M in trailing free cash flow, a sub-1 price-to-sales multiple, and planned cost savings near $70M, the setup favors a mid-term long trade. The key risks are execution on restructuring, high le…
Torex Gold (TORXF) is trading at a single-digit P/E and just above its 20-day average while fundamental signals point to a shift from capex intensity to free cash generation. This trade idea lays out an actionable mid-term long: entry at $43.95, stop at $37.00, target $58.00 (roughly 32% upside). Catalysts include production stability, dividend ren…
TDK is a cyclical industrial with secular exposure to electrification and AI. We like a long trade into perceived M&A optionality and accelerating AI demand for advanced sensors, capacitors and power components. Entry at $95.00, stop at $82.00, target at $120.00 for a 180 trading day horizon.
Fiserv plunged on news the CEO is leaving, but the drop looks driven by sentiment, not fundamentals. With $4.1B in free cash flow, a market cap near $25.6B and a below-market P/E of ~9, the risk-reward favors a tactical long over the next 45 trading days if guidance holds and management executes its 'One Fiserv' plan.
Shares of Ameriprise (AMP) have been punished on headlines and regulatory scrutiny around cash sweep programs. The market is pricing in a worst-case earnings and franchise hit; the fundamentals - strong free cash flow, a sub-12x P/E, and a high ROE - argue this is an attractive entry. This trade idea lays out an actionable long, with precise entry,…
BioCryst (BCRX) is executing on a two-pillared strategy: scale ORLADEYO's profitable, growing U.S. business while adding navenibart, a long-acting monoclonal antibody, for patients who prefer infrequent dosing. Strong Q1 revenue, a $70M upfront licensing deal in Europe, recent conference data, and free cash flow generation create a favorable risk/r…
